Article
Sorafenib Combined with DOAP Regimen for the Treatment of BRAF V600E-Negative Langerhans Cell Sarcoma: A three-year follow-up result
2024-09-02
Abstract excerpt
<h4>Objective: </h4> The purpose of this study is to investigate the clinical efficacy of the combination therapy of sorafenib and DOAP (doxorubicin, vincristine, cytarabine, and prednisone) in the treatment of a case of Langerhans cell sarcoma (LCS) negative for BRAF V600E mutation. Furthermore, we aim to retrospectively analyze the clinical characteristics, diagnosis, treatment, and prognosis of LCS. <h4>Method...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b7f1f2b5-ba34-5ebf-bb26-6bf755b2e678
- DOI
- 10.22541/au.172528798.87557705/v1
